

Generation of Functioning Nephrons by Implanting Human Pluripotent Stem Cell-Derived Kidney Progenitors

Ioannis Bantounas,¹ Parisa Ranjzad,^{1,2} Faris Tengku,¹ Edina Silajdžić,¹ Duncan Forster,³ Marie-Claude Asselin,³ Philip Lewis,¹ Rachel Lennon,^{1,2,4} Antonius Plagge,⁵ Qi Wang,¹ Adrian S. Woolf,^{1,2} and Susan J. Kimber^{1,*}

¹Division of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science Centre, Manchester, UK

²Royal Manchester Children's Hospital, Manchester, UK

³Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK

⁴Wellcome Trust Centre for Cell-Matrix Research, Division of Cell Matrix Biology and Regenerative Medicine, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK

⁵Institute of Translational Medicine, University of Liverpool, Liverpool, UK

*Correspondence: sue.kimber@manchester.ac.uk

<https://doi.org/10.1016/j.stemcr.2018.01.008>

SUMMARY

Human pluripotent stem cells (hPSCs) hold great promise for understanding kidney development and disease. We reproducibly differentiated three genetically distinct wild-type hPSC lines to kidney precursors that underwent rudimentary morphogenesis *in vitro*. They expressed nephron and collecting duct lineage marker genes, several of which are mutated in human kidney disease. Lentiviral-transduced hPSCs expressing reporter genes differentiated similarly to controls *in vitro*. Kidney progenitors were subcutaneously implanted into immunodeficient mice. By 12 weeks, they formed organ-like masses detectable by bioluminescence imaging. Implants included perfused glomeruli containing human capillaries, podocytes with regions of mature basement membrane, and mesangial cells. After intravenous injection of fluorescent low-molecular-weight dextran, signal was detected in tubules, demonstrating uptake from glomerular filtrate. Thus, we have developed methods to trace hPSC-derived kidney precursors that formed functioning nephrons *in vivo*. These advances beyond *in vitro* culture are critical steps toward using hPSCs to model and treat kidney diseases.

INTRODUCTION

The mammalian kidney generates and eliminates waste products and is essential for life. Annually, 2.6 million people worldwide receive dialysis or kidney transplantation for end-stage kidney disease (ESKD), while around 2.2 million people with ESKD die prematurely, unable to access treatment (Liyanaage et al., 2015). Kidney transplants are in short supply and an adult on long-term dialysis has an average life expectancy of barely a decade (Neild, 2017). Therapies that prevent the progression of chronic kidney disease to ESKD are therefore urgently needed.

The definitive human kidney, the metanephros, initiates at 5 weeks of gestation (Woolf and Jenkins, 2015) when it is composed of metanephric mesenchyme (MM) around a ureteric bud (UB), both derived from intermediate mesoderm. Over the next month, MM differentiates to form the first nephrons, each containing a glomerulus in continuity with proximal and distal tubules. Concurrently, the UB branches serially to form collecting ducts that fuse with nascent nephrons. As the glomerulus matures, endothelia invade clusters of podocytes, forming capillary loops. The adjacent endothelia and epithelia are separated by the glomerular basement membrane (GBM), and the three components act as a functional unit that filters blood.

The resulting ultrafiltrate is then modified by tubules to form definitive urine.

Given that kidney disease can result from genetic aberrations (Kerecuk et al., 2008; Hildebrandt, 2010) *in utero*, there is an urgent need to better understand the development of human kidneys. Although mouse models have been informative about developmental mechanisms (Woolf and Davies, 2013; McMahon, 2016), they do not always exactly phenocopy human kidney diseases that result from mutations of homologous genes (Woolf and Jenkins, 2015; Kerecuk et al., 2008). Clearly, human models are the ideal systems for understanding organogenesis in relation to human health and disease.

The use of expandable human pluripotent stem cells (hPSCs) with their plasticity in response to developmental signals is a promising and logical choice for many disease therapies (Carpenter et al., 2009; Cheng et al., 2014; Ichimura and Shiba, 2017) and for modeling monogenic diseases (Ebert et al., 2009; Shi et al., 2017). This includes making kidney cells to model ESKDs, or for therapy. Several *in vitro* studies have demonstrated that a defined cocktail of growth factors and small molecules, applied in a timed sequence to hPSCs, can result in primitive kidney morphogenesis in 2D (Narayanan et al., 2013; Kang and Han, 2014; Lam et al., 2014; Takasato et al., 2014) and in 3D (Xia et al., 2014; Takasato et al., 2015; Ciampi et al., 2016) cultures.



This led to the development of immature kidney structures, allowing interaction between UB and MM tissues and their co-operative development. This technology is beginning to show promise to model both genetic (Freedman et al., 2015) and acquired (Morizane et al., 2015) kidney diseases. Questions remain, however, regarding the reproducibility of the differentiation protocols, replicability between hPSC lines, and the degree of maturity and function that can be obtained. In 3D transwell formats, kidney structures progress further giving some regional organization (Takasato et al., 2015), but the kidney progenitors are necessarily limited in their growth and functional differentiation because, for example, they lack a blood supply.

With these limitations in mind, we used three wild-type hPSC lines from different genetic backgrounds and reproducibly differentiated them into kidney progenitors *in vitro*. They underwent rudimentary morphogenesis and expressed MM/nephron and UB/collecting duct lineage markers. Using bicistronic lentiviral reporters to trace the hPSC derivatives *in vivo*, we showed that the kidney progenitors formed functional nephrons following subcutaneous implantation. Compared with *in vitro* culture, hPSC-kidney differentiation was dramatically improved with the generation of glomeruli, containing human capillaries and podocytes separated by regions of mature basement membrane. These are critical advances toward using hPSCs to model and treat kidney diseases.

RESULTS

Gene Expression Patterns in hPSCs Induced to Form Kidney Precursors in Culture

To obtain kidney progenitor cells for transplantation, we first determined whether three characterized human embryonic stem cell (hESC) lines, clinical grade MAN13, MAN11 (Ye et al., 2017; Canham et al., 2015), and HUES1 (Cowan et al., 2004; Oldershaw et al., 2010) had the potential to differentiate into kidney progenitors using an established protocol (Takasato et al., 2014). This comprised exposure to CHIR99021, a glycogen synthase kinase-3 inhibitor, for 3 days before switching to FGF9 and heparin for 10 days, followed by basal STEMdiff APEL medium alone until day 30 (Figure 1A). Using qPCR, we documented the expression of 17 key transcripts characterizing mesoderm, intermediate mesoderm, MM and its nephron segment derivatives, and the UB and its collecting duct derivatives.

In three separate experiments with MAN13, transcripts for *T (Brachyury)* and *MIXL1*, mesodermal/mesendodermal transcription factors, peaked 1 day into the protocol (Figure 1B). As these were downregulated, *OSR1* and *PAX2*, intermediate mesoderm transcription factor markers, were

upregulated: *PAX2* is also expressed in UB/collecting ducts and MM, and *OSR1* in MM. The expression of both transcripts was maintained during the rest of the *in vitro* protocol with a slight decrease in *PAX2* toward day 30. In the first 7–10 days, transcripts for a battery MM/nephron lineage transcription factors (*LHX1*, *SIX2*, *WT1*, *HOXD11*, and *SALL1*) increased, with an early peak in *SALL1* and *HOXD11* and subsequent robust *SIX2* and *WT1* expression. Up to day 30, there was a progressive increase in levels of *AQP1*, encoding a proximal tubule water channel, with variable upregulation of *PODXL*, encoding a podocyte sialomucin, between days 10 and 20. Transcripts for *PDGFRB*, a marker of pericytes and required for endothelial development, increased up to day 20, while those for *FOXD1*, a kidney stromal progenitor and endothelial development marker, increased after day 10. *SALL4* and *HOXB7*, transcription factors of the UB lineage, were induced in the first week of the protocol, whereas *AQP2*, which encodes a collecting duct water channel, rose progressively up to day 30. *UMOD* transcripts, marking the thick ascending limb of the loop of Henle, were also detected during differentiation. Similar patterns of transcript expression were recorded in HUES1 and MAN11, exposed to this differentiation protocol (Figure S1). These results suggested reproducibility of the protocol for obtaining kidney cells from different hESC lines, and we focused on one, MAN13, for the rest of the study.

Rudimentary Morphogenesis by hPSC-Derived Kidney Precursors in 2D Culture

On day 12 of the 2D protocol, cultures comprised confluent lawns, interspersed with zones of increased cell density (Figure 2). We immunostained cultures for transcription factors expressed by MM/nephron (*WT1*, *SIX2*, and *PAX2*) and UB/collecting duct (*GATA3* and *PAX2*) lineages, and for the epithelial adhesion protein *CDH1* (E-cadherin). We observed *WT1*+ cell clusters, some with *CDH1*+ cores (Figure 2A). *In vivo*, glomerular podocytes, as well as induced MM, express *WT1* but immunostaining cultures for the podocyte marker nephrin, and for the distal convoluted tubule marker *TRPV5*, proved negative (data not shown). *SIX2*+ cells were mostly detected in loose populations surrounding *CDH1*+ structures (Figure 2B), although we occasionally observed *CDH1*+/*SIX2*+ clusters (Figure 2C), likely representing initial epithelialization within the MM/nephron lineage. *PAX2*+ clusters were visualized, some containing *CDH1*+ cores (Figure 2D). For *GATA3*, two patterns were observed: first, some *CDH1*+ tubule-like structures contained subsets of *GATA3*+ cells (Figure 2E), consistent with a collecting duct identity; the other pattern comprised scattered *GATA3*+ cells around *CDH1*+ aggregates (Figure 2F), as described in a similar protocol (Takasato et al., 2015). After 30 days of differentiation *in vitro*,




Figure 1. Differentiation of MAN13 hPSC to Kidney Lineages in 2D Culture

(A) Schematic of the 30 day differentiation protocol depicting the timing of application of CHIR99021 and FGF9/heparin. The time point of cell harvest for implantation into mice is also indicated (*d12*, in red).

(B) qPCR profiling of 17 transcripts at 11 time points over 30 days. The results for three independent experiments are shown in blue, red, and green, with levels of target transcripts normalized to *GAPDH* expression. The characteristic tissue/lineage that expresses each gene *in vivo* is indicated above the graph for each transcript. The black vertical line in each graph indicates the time of collection of cells for implantation into mice.




Figure 2. Immunocytochemistry of hPSC Cultures

MAN13 cells were differentiated for 12 days *in vitro*, when rudimentary morphogenesis had begun. Cultures were co-stained with the epithelial cell-cell adhesion protein CDH1 (left frames) and transcription factors (middle frames) to detect: MM-derived cells (WT1 or SIX2); UB-derived tubules (GATA3); and PAX2, expressed in both lineages. Right-hand frames show merged images (red CDH1 and green nuclear proteins). (A) A WT1+ cell cluster with a central zone expressing CDH1. (B) Typically, loose SIX2+ cells surrounded CDH1+ zones. (C) Occasionally, subsets of SIX2+ cells appeared to co-express CDH1. (D) A PAX2+ cluster with a central zone expressing CDH1. (E) A CDH1+ tubule-like structure containing a subset of GATA3+ nuclei. (F) In other areas, loosely packed GATA3+ cells surrounded CDH1+ structures. Scale bars, 40 μm .

more complex cell clusters were seen (Figure S2). Even at this more advanced stage, SIX2+ cells were present, consistent with potential for further nephrogenesis (Kobayashi et al., 2008). However, because MM and UB progenitor populations were clearly present at day 12, we reasoned that this would be a suitable point to test their further differentiation after implantation *in vivo*.

hPSC Differentiation in 3D Organoid Cultures

Aiming to further enhance glomerular morphogenesis we evaluated alternative protocols. Takasato et al. (2015) differ-

entiated hESCs for up to a week in 2D culture as above, but then subjected them to a pulse of CHIR99021, after pelleting and placing at a medium-air interface. We replicated their formation of 3D organoids with more mature kidney structures compared with 2D culture (Figure S3), but, although glomerular structures were formed, they were immature and not identical to mature glomeruli *in vivo*. In particular, glomerular tufts lacked capillaries and did not express mature collagen IV. We reasoned that maturation may require more time and factors in the *in vivo* environment and set out to evaluate kidney development *in vivo*.




Figure 3. Transduction of MAN13 hPSCs with a Lentiviral Vector Expressing a Bicistronic iRFP-E2A-Luciferase Cassette

(A) Diagram of the expression cassette showing the two reporter genes and the *EF1α* promoter. (B) iRFP fluorescence in transduced cells. (C and D) Viability and cytotoxicity (mean ± SEM, n = 4) in MAN13 cultures transduced with lentivirus (*LV-iRFP/Luc*), with no significant difference compared with untransduced controls (*LV-CTRL*). As a positive “death” control, MAN13 cells were treated with 500 nM staurosporine for 24 hr.

Lentivirus-Mediated Transduction of hPSCs with Reporter Genes

To trace implanted kidney progenitors *in vivo*, we generated an integrating lentiviral vector carrying a bicistronic cassette, expressing a near infrared fluorescent protein (iRFP, emission at 720 nm) and firefly luciferase, both under the control of the *EF1α* promoter (Figure 3A). Transduction of MAN13 hESCs resulted in robust expression of the fluorescent protein (Figure 3B). Transduction did not affect viability nor was it toxic (Figures 3C and 3D). Furthermore, up to day 30 of the *in vitro* protocol, both the parent and transduced lines showed similar morphogenesis (Figure 3E) and patterns of transcript for *T*, *OSR1*, *SIX2*, *PAX2*, and *WT1* (Figure 3F).

Assessment of Pluripotency in Lentivirus-Transduced hESCs by Teratoma Assay

To determine whether lentiviral labeling compromised the pluripotent potential of hPSCs we subcutaneously implanted MAN13 parent hESCs and transduced MAN13 hESCs in the backs of *SCID/beige* mice as aliquots of one million cells in Matrigel. Mice were culled when an implanted cell mass reached a maximum 1.6 cm across (Table S1). This protocol led to mice being culled at similar times (parent line, 38.8 ± 1.2 days; transduced line, 44.6 ± 1.2 days; mean ± SEM; p = 0.07, Student’s t test). Each line was similarly efficient at forming histologically confirmed masses (20 out of 24 sites in the parent versus 29 out of 36 in the transduced cells; p = 1.00, Fisher’s exact test, two-tailed) that were of similar sizes (parent line, 1.13 ± 0.07 cm versus transduced line, 0.98 ± 0.07 cm; p = 0.11, Student’s t test). Histology revealed that all masses had hallmarks of teratomas (Figure S4A), containing endodermal (Figure S4B), mesodermal (Figure S4C), and ectodermal (Figure S4D) derivatives. Teratomas formed from lentivirus-labeled cells were detectable using bioluminescent imaging of living mice (Figure S4E), and expressed luciferase (Figure S4F) and human mitochondrial antigen (Figure S4G), confirming their hESC origin.

Subcutaneous Implantation of Kidney Progenitor Cells Derived from Labeled hPSCs

Since lentiviral labeling of MAN13 hPSCs had no detrimental effect on hESC pluripotency, self-renewal, or differentiation to kidney progenitors in 2D culture, we reasoned

(E) Examples of transduced and untransduced differentiating MAN13 cultures assessed by immunocytochemistry for SIX2, WT1, and CDH1.

(F) Similar qPCR profiles of transduced versus parent cells during 2D kidney differentiation. A representative experiment of three independent biological repeats is shown for each line.

Scale bars, 200 μm in (B) and 90 μm in (E).




Figure 4. Subcutaneous Implantation into *beige/SCID* Mice of Luciferase-Labeled MAN13-Derived Kidney Precursor Cells Harvested at Day 12 in 2D Culture

(A–D) Histological overview 12 weeks after transplantation. The implanted cells have formed a differentiated mass (A). Boxed areas indicate the following: (B) differentiated nephrons; (C) cartilage; and (D) poorly differentiated tubules and stroma.

(E) Side and dorsal views showing bioluminescence in a living mouse that had received kidney precursor transplants 12 weeks previously.

(F) Immunostaining (brown) for luciferase in area containing nephron-like structures.

(G) Immunostaining (brown) for human mitochondria, arrows indicate tubules.

Sections in (F) and (G) are not counterstained. Scale bars, 100 μ m (A) and 50 μ m in (B)–(D), (F), and (G).

that labeled kidney precursor cells generated in 2D culture would be suitable for further differentiation *in vivo*. Based on our *in vitro* data, we reasoned that progenitors on day 12 of 2D differentiation would be committed to kidney lineages but still able to respond in the *in vivo* environment, while having lost the potential to form teratomas. Therefore, on day 12, lentivirus-labeled MAN13-derived kidney progenitors were injected subcutaneously into *SCID/beige* mice, as for hESCs. Mice were followed for up to 12 weeks, at which time no mouse had an implant site with a cellular mass of 1.6 cm. In fact, masses were only rarely detected on external inspection and palpation, leading to harvesting at 84.3 ± 0.2 days (Table S1), significantly longer ($p < 0.001$, Student's *t* test) than for the hESC implants. Only 9 of 32 implant sites contained histologically identified masses, significantly fewer than for undifferentiated hESC implants ($p < 0.001$, Fisher's exact test, two-tailed). Moreover, these masses were an average diameter of 0.61 ± 0.11 cm, significantly smaller ($p < 0.05$, Student's *t* test) than for hESC-derived teratomas.

Histology of tissues generated from transplanted MAN13 kidney precursors (Figure 4A) was strikingly different from that of teratomas. The kidney precursor implants

comprised differentiated kidney structures with glomeruli and tubules (Figure 4B), as well as occasional islands of cartilage (Figure 4C) and poorly differentiated metanephric tissues (Figure 4D). The masses detected at autopsy corresponded to the bioluminescent areas detected in living mice using non-invasive imaging (Figure 4E), and reacted with antibodies to luciferase (Figure 4F) and human mitochondrial antigen (Figure 4G) in sections, confirming that they were composed of human cells. There was some variation in the degree of differentiation between implants: for example, the mass in Figure S5 contained prominent zones in which isolated glomeruli were surrounded by mesenchyme-like cells and primitive tubules. From comprehensive histological analysis, of all nine masses derived from implanted kidney progenitors, we concluded that teratomas were not generated and that the cells were able to survive and continue to differentiate to kidney tissue.

Next, we implanted a second group of mice with MAN13 cells, some differentiated for 12 days, and others for 19 days, using the *in vitro* 2D protocol. The day 12 implants formed glomeruli and tubules, similar to those in the first study, above, at 7/20 injected sites. Although not visible



externally, the day 19 implants resulted in a few small masses observed by luminescence in a similar proportion 8/20, injected sites at 12 weeks after implantation (Table S1). These exhibited an immature morphology (Figure S6) compared with those generated from day 12 progenitors. This suggests there is likely to be a critical stage of kidney differentiation in culture beyond which dissociated cells lose their plasticity and ability to respond to an *in vivo* environment, or to each other and undergo only limited nephrogenesis.

Detailed Phenotyping of Implant Tissues from hPSC-Derived Kidney Precursor Cells

Next, we characterized the kidney structures formed within the implants. Glomeruli contained red blood cells in their tufts, consistent with a blood supply, and Bowman spaces were observed continuous with tubules (Figure 5A). Glomeruli were immunoreactive with antibodies raised against the mature GBM proteins, collagen α -3 (IV) and laminin β 2, and to anti-pan-collagen IV, which was also reactive with basement membranes of nearby tubules (Figures 5B–5D). Podocyte-like cells in glomerular tufts were detected with antibodies to synaptopodin, WT1, and podocalyxin (Figures 5E–5G). Podocin (Figure 5H) and nephrin (Figure 5I), podocyte slit diaphragm proteins, were prominent on the basal aspect of podocytes. Platelet-derived growth factor receptor B staining was present in the center of the glomerular tuft where mesangial cells reside (Figure 5J). Mesangial-like cells were apparent in this location by transmission electron microscopy (TEM) (Figure 5K and Movie S1). Ki67, was rarely detected in glomeruli, but proliferative cells were prominent in nearby less differentiated areas (Figure 5L).

An antibody against a human PECAM epitope revealed networks of capillaries within tufts of the majority of glomeruli (Figure 5M). We also detected larger, arteriole-like, vessels near glomeruli within the implant. Using double immunostaining, luciferase-expressing rhomboidal pericyte-like cells were closely associated with PECAM+ endothelia in these vessels (Figure 5N). In addition, glomerular podocytes were positive for the vascular growth factor VEGFA (Figure 5O). Notably, the PECAM antibody did not react with mouse kidney sections (Figure 5P). Thus implant glomeruli are vascularized, and endothelia in the glomerular tufts, and vessels around the glomeruli, can derive from implanted human cells. Moreover, the day 12 kidney precursor-derived tissues *in vivo* are morphologically and molecularly substantially more mature than those formed in 3D organoid cultures (compare Figure 5 with Figure S3). *In vivo*, the glomeruli expressed all the markers tested and, crucially, they were vascularized in a pattern similar to native glomeruli *in vivo*, unlike in the *in vitro* 3D organoid cultures.

TEM revealed that glomeruli in implants possessed a characteristic arrangement of podocytes on the outer surface of blood capillaries (Figure 6A). Those capillaries often contained red blood cells, providing further evidence that the glomeruli are connected to the blood supply of the host. Higher-power TEM images of podocyte-capillary interfaces revealed that some had an ultrastructure indistinguishable from that seen in mature glomeruli (Figure 6B), with podocytes possessing the characteristic foot processes joined by slit diaphragm-like structures and urinary spaces visible under the foot processes (Figure 6C). Also present was a fused GBM (Figure 6C). Other areas, showed a less-mature GBM, sometimes double layered with two laminae (Figure 6D), as occurs in glomerulogenesis (Sariola, 1984). Implant tissues also contained tubules, some being positive for nephron-segment markers: cubulin (Figure 7A) and aquaporin 1 (Figure 7B) in proximal-like tubules, uromodulin in thick ascending loops of Henle (Figure 7C), and TRPV5 in distal convoluted-like tubules (Figure 7D). Larger-diameter branching tubules expressed CDH1 (Figure 7E), and others GATA3, suggesting that they were collecting ducts (Figure 7F). TEM revealed microvilli and primary cilia in the tubules (Figures 7H and 7I).

Since human glomeruli with patent, perfused capillary loops were present, we investigated whether glomerular filtration might be occurring, using day 12 kidney precursor cells with tissue harvested after 11 weeks. Some mice were intravenously administered fluorescein isothiocyanate-labeled 10 kDa dextran 1 hr prior to culling, as this is filtered by glomeruli and then reclaimed by proximal tubules (Woolf et al., 1990). Histology revealed a subset of tubules with fluorescence, most marked in the apical zone (Figure 7J), with negligible background fluorescence in uninjected mouse implants (Figure 7K).

DISCUSSION

In this study, we have demonstrated that different hPSC lines can be reproducibly induced to form kidney precursors *in vitro*, which can further develop *in vivo* to generate mature kidney structures, with vascularized glomeruli that can filter blood to make ultrafiltrate that is processed by adjacent tubules.

Variation in outcome between lines and protocols has been an issue with protocols for obtaining PSC kidney cells in culture. We showed that three wild-type hESC lines exhibited consistent differentiation in 2D culture, despite different genetic backgrounds (Ye et al., 2017). Furthermore, we labeled hPSCs with reporter genes for lineage tracing without compromising their differentiation potential, allowing hESC-derived kidney progenitor cells to be traced using non-invasive bioluminescence imaging after




Figure 5. Histology of Glomeruli Generated from Implanted Luciferase-Labeled MAN13-Derived Kidney Precursor Cells Harvested at Day 12 of 2D Culture

Images in (A)–(O) are implants, whereas (P) is an adult mouse glomerulus. (A) and (I) were counterstained with H&E; (B), (C), (M), and (P) were counterstained with hematoxylin only; other sections were not counterstained. All frames are bright-field views apart from (K), which is TEM and (N), which is epifluorescence. g indicates a glomerulus, t indicates a tubule, p indicates a podocyte, and m indicates a mesangial cell.

(A) Glomerulus with red blood cells in its tuft. Note the lumen of the tubule in continuity with the Bowman space of the glomerulus.

(B) Collagen α -3 (IV) immunostaining (brown) in a GBM-like pattern.

(C) Pan-collagen IV immunostaining (brown) in a glomerulus and nearby tubules.

(D) Laminin B2 (brown) immunostaining in two glomeruli but negligible in the tubule.

(E) Synaptopodin IHC (brown) in a linear pattern on the basal aspect of the podocytes.

(F) WT1 IHC (brown) in podocyte nuclei.

(G) Podocalyxin IHC (brown) in podocytes.

(H) Podocin immunostaining (brown) in a linear pattern at the basal side of podocytes (arrows indicate apical sides of podocytes).

(I) Nephryn immunostaining (brown) in a glomerulus. The boxed area is enlarged on the top right corner of the frame; arrows indicate nephryn in a linear pattern adjacent to a capillary loop containing a red blood cell.

(J) Platelet-derived growth factor receptor B (PDGFRB) IHC (brown) in the center of a

glomerular tuft where mesangial cells reside (boxed area). Arrows indicate additional immunostaining in Bowman capsule.

(K) TEM of a similar area as depicted by a box in (J). m marks a mesangial-like cell and p indicates podocytes.

(L) Ki67 immunostaining (brown) marking proliferation in more poorly differentiated cells near a glomerulus and a tubule; occasional positive nuclei (arrows) were detected in tubules and Bowman capsules.

(M) PECAM immunostaining (brown) shows an extensive capillary network in glomerular tufts.

(N) PECAM (red) and luciferase (green) double immunostaining. The white asterisk marks the lumen of a small artery that is continuous with the capillary network in the glomerular tuft; the white dotted line marks the Bowman capsule. Note that luciferase-expressing cells are closely associated with endothelia whose luminal surface is positive for PECAM.

(O) VEGFA immunostaining (brown) was prominent in podocytes (arrows).

(P) Mouse glomerulus is not reactive with the anti-human PECAM monoclonal antibody.

Scale bars, 50 μ m in (A)–(J) and (L)–(P) and 500 nm in (K).

implantation into mice where they form functioning nephrons.

As shown here and previously (Takasato et al., 2015), 3D transmembrane organotypic cultures can modestly

advance kidney morphogenesis from PSCs beyond 2D cultures. However, by implanting differentiating cells from 2D cultures *in vivo* we have substantially improved their maturity. Implanted progenitors survived subcutaneously for




Figure 6. TEM of a Glomerulus Generated from Implanted MAN13-Derived Kidney Precursor Cells

(A) TEM overview of a capillary lumen (CL) containing a red blood cell (RBC) and lined by endothelial cells (E). Podocyte-like cells (PC) and endothelia abut a shared basement membrane (white arrows).

(B) Diagram of ultrastructure of a mature glomerulus showing the spatial relationships between the capillary lumen (CL, red), endothelial cells (E, light blue), and podocytes (PN, dark blue, is a podocyte nucleus, and PC, green, is podocyte cytoplasm). Endothelia and podocytes rest on a shared trilaminar GBM, with the central lamina densa (black) flanked by the lamina rara interna on the endothelial side and lamina rara externa on the podocyte side (both light grey). Yellow arrows indicate electron dense slit diaphragm like structures joining podocyte foot processes that abut the GBM. Asterisks indicate spaces between the foot processes that receive glomerular ultrafiltrate.

(C) High-power TEM showing mature organization of trilaminar GBM (between white arrowheads) and dark slit diaphragm-like structures (yellow arrowheads) between podocyte foot processes. Asterisks indicate urinary spaces between foot processes.

(D) TEM of another zone showing a less mature appearance. This GBM has two dark lamina densae (white arrow), as occurs in nascent glomeruli.

Scale bars, 1 μm in (A), 200 nm in (C), and 500 nm in (D).

3 months, forming markedly more mature kidney structures than reported previously. Notably, mature vascularized glomeruli were observed. Evidence for the maturity of these glomeruli comes from the observations that they expressed mature GBM proteins, laminin $\beta 2$ and collagen $\alpha 3$ (IV) (St John et al., 2001), with a fused trilaminar structure, as well as podocyte processes and slit diaphragms. Type IV collagen is an essential BM component and forms three distinct networks from combinations of six different α chains. Networks formed from trimers of $\alpha 1,1,2$ predominate in early mouse glomerular development, and there is an isoform switch to the $\alpha 3,4,5$ network, which is most abundant in mature GBM (Harvey et al., 1998). Using α chain-specific antibodies we detected collagen $\alpha 3$ (IV) in implant glomeruli indicative of assembly of the mature $\alpha 3,4,5$ network. The detection and distribution of both podocin and nephrin at the basal aspect of podocytes within differentiated implants supports the conclusion that slit diaphragms were maturing within these glomeruli. Furthermore, the functionality of PSC-derived whole nephrons has been demonstrated *in vivo*: we detected uptake by tubule cells of low MW, filterable, fluorescent dextran injected into the host circulation. This level of maturity is remarkable given that the progenitor cells were implanted at an ectopic site, showing that PSC kidney development, such as embryonic/fetal kidney development, exhibits a high level of autonomy. This may be an advantage for

future use of PSC kidney progenitors therapeutically, since they require limited instructive signaling from their environment in order to develop and may be more likely to develop and function normally in a suboptimal environment.

A key event in glomerulogenesis, prerequisite for delivery of blood for filtration, is invasion of the glomerular tuft by endothelia that form capillary loops. We observed organoids rich in glomeruli with WT1+ tufts in hPSC-derived kidney precursors maintained in 3D organ culture. Although interstitial spaces around the glomeruli contained PECAM+ cells, endothelia were rarely detected in glomerular tufts, consistent with the observations of Takasato et al. (2015). In contrast, we found that glomeruli formed after subcutaneous implantation of hESC-derived kidney precursors, had prominent capillaries, some containing red blood cells, consistent with perfusion. The human origin for PECAM+ glomerular capillaries in implants was confirmed by reactivity with the human-specific PECAM antibody, not seen in mouse kidney. We cannot exclude the possibility that a proportion of endothelia within implants originate from the host, and indeed connections between the two vasculatures must exist for perfusion to take place. We found that the glomeruli that formed in 3D organ culture had only diffuse low expression of VEGFA, whereas prominent immunostaining was detected in podocytes of glomeruli formed by implanted cells, supporting the




Figure 7. Tubules Formed from Implanted MAN13-Derived Kidney Precursor Cells and Evidence of Nephron Functionality

(A)–(G) show bright-field IHC, with (B), (C), (D), and (F) counterstained with hematoxylin. (H) and (I) are TEM images. (J) and (K) are epifluorescence imaging.

(A) Brush border-like immunostaining (brown) with antibody to cubulin, a proximal tubule protein, in a subset of tubules. A negative tubule is marked with a red asterisk.

(B) Aquaporin 1 immunostaining (brown) in a subset of tubules; another (asterisk) is negative. Note, as expected, aquaporin 1 is also present in glomerular and interstitial capillaries.

(C) Immunostaining for uromodulin (brown), a protein in thick ascending limbs of loops of Henle.

(D) Immunostaining for TRPV5 (brown), a protein that marks distal convoluted tubules; another tubule (asterisk) and glomeruli are negative.

(E) CDH1 immunostaining (brown) in large branched tubules.

(F) GATA3 immunostaining (brown) in a large tubule; the smaller tubule (asterisk) is negative.

(G) Negative control: rabbit secondary antibody applied but primary antibody omitted.

(H) Overview TEM image of a cross-section of a tubule, outlined in red dashes.

(I) High-power TEM image of central zone of tubules showing a primary cilium (red arrow); above its basal body is a zone with cross-sections of a cluster of microvillus-like structures.

(J) Section from a kidney progenitor-derived mass harvested from a mouse intravenously injected with low-molecular-weight, fluorescein isothiocyanate (FITC)-labeled dextran. White dashes surround a cross-section of a tubule containing green fluorescence, most marked in its apical, central, zone. The yellow arrow indicates a small blood vessel that itself contains injected FITC-dextran.

(K) An equivalent section from an implant in a mouse not injected with FITC-dextran shows background green fluorescence only.

Scale bars, 50 μ m in (A)–(G) and (J)–(K), 5 μ m in (H), and 0.5 μ m in (I).

conclusion from mice, that VEGFA is needed for glomerular maturation (Tufro, 2000; Eremina et al., 2003). Notably, glomeruli formed from implants also contained mesangial-like cells which provide mechanical integrity to capillary loops *in vivo*.

The key function of the kidney is to filter blood, generating an ultrafiltrate that is modified by tubules to form definitive urine. Our implants established the essential components for filtration: blood-perfused capillaries, podocytes, and regions of mature GBM between these cells.

After intravenous injection of fluorescently labeled low-MW dextran glomerular filtration followed by tubule uptake of fluorescent dextran in a subset of PSC kidney tubules was observed. Others have transplanted intact human embryonic metanephric kidneys, but not PSC-derived kidney tissue, into immunodeficient mice where they differentiated into urine producing kidneys (Dekel et al., 2002, 2003). Other studies have also attempted to generate functional glomeruli from human SCs. Xinaris et al. (2016) mixed human amniotic SCs with mouse metanephric



kidney cells to form chimeric organoids and transplanted these into mice: human cells contributed to the formation of some functional glomeruli, assessed by the uptake of infused BSA. Using hPSCs carrying a podocyte-specific promoter-reporter gene, [Sharmin et al. \(2016\)](#) generated podocytes and mixed them with a human endothelial cell line. After transplanting the mixture under the kidney capsule, they reported the presence of vascularized glomeruli containing donor-derived podocytes. In neither study did a whole kidney-like organ form from a single source of human cells, as we have demonstrated for hPSCs.

The technological advances we have generated will facilitate use of hPSC-derived kidney tissues as models of genetic human disease. As the hPSCs differentiate toward kidney progenitors *in vitro*, they expressed the transcription factors PAX2 and SALL1, respectively mutated in the human renal coloboma ([Sanyanusin et al., 1995](#)) and Townes-Brocks ([Faguer et al., 2009](#)) syndromes featuring kidney malformations. We show that glomerular proteins that can be mutated in blood filtration diseases were present in implant glomeruli. These genetic diseases include congenital nephrotic syndrome (nephrin and podicin; [Hildebrandt, 2010](#)), Alport syndrome (collagen genes, including *COL4A3*; [Lemmink et al., 1994](#)), Pierson syndrome (*LAMB2*; [Zenker et al., 2004](#)), and Frasier syndrome (*WT1*; [Barboux et al., 1995](#)). Other proteins essential for terminal differentiation of kidney tubules were also expressed in the implants: cubulin present in the apical brush border of proximal tubules, where it functions with megalin in uptake of small proteins; uromodulin, an apical protein in ascending loops of Henle and mutated in medullary cystic kidney disease ([Ovunc et al., 2011](#); [Turner et al., 2003](#)); and TRPV5, involved in calcium transport in the distal convoluted tubule. Combining our current technology with CRISPR/Cas9 gene editing of hPSCs ([Freedman et al., 2015](#)) with mutation generation, or correction of (patient-derived) mutations and evaluation of implanted kidney tissues *in vivo* will provide much improved insight into disease mechanisms and allow more focused drug discovery.

Numerous limitations will need to be overcome before a whole functional renal tract can be generated from hPSCs. First, the mammalian kidney receives 20% of the cardiac output, to generate the required high blood flow and hydrostatic pressures within glomerular capillaries, which facilitate glomerular ultrafiltration. Although PSC-kidney precursor cells-derived tissues lack large arteries, in future, placing transplanted cells near arterio-venous loops may enhance the blood supply, as used in transplantation of, e.g., embryonic liver ([Fiegel et al., 2010](#)). Second, although the kidney-like tissues that formed contained numerous nephrons, branched collecting ducts were sparse. In future, modulation of *in vitro* protocols to enhance the UB/collect-

ing duct lineage ([Taguchi et al., 2014](#)) could be employed. Our study has also gone some way to demonstrating the safety of implanting kidney progenitors *in vivo*: none of the implants showed typical teratoma three-germ-layer differentiation. This is promising for the prospect of using these cells to generate human kidney repair in the future, although many challenges remain including development and survival in a hostile, damaged kidney environment. Evaluation up to a year after transplantation, will be needed to determine the longer-term fates of the cells. Finally, a functional kidney needs to deliver urine into a lower urinary tract. No structures were formed that morphologically resembled either the renal pelvis or the ureter and immunostaining for the urothelial marker uroplakin II was negative (data not shown). In future, therefore, it may be necessary to fuse a host ureter with the kidney tubules that form after implantation of PSC-derived kidney precursors, thus forming a single functional renal tract.

Although there is still room for improvement in the differentiation and maturation efficiency, we have provided proof-of-principle that, when hPSC-derived kidney progenitors are implanted *in vivo*, they can produce more mature kidney structures than in 2D or 3D culture, with near normal patterns of glomerular vascularization. We have generated functional nephrons from hPSCs and shown that their glomeruli are molecularly and ultrastructurally mature. This work greatly advances our progress toward using stem cells for kidney repair and as tools to investigate human genetic diseases affecting the kidney.

EXPERIMENTAL PROCEDURES

hPSC Culture and Differentiation

hESC lines, MAN11 and MAN13 ([Ye et al., 2017](#)) and HUES1, kind gift from [Cowan et al. \(2004\)](#), were cultured in our feeder-free system modified from that described previously ([Baxter et al., 2009](#)). MAN11 and MAN13 were cultured on human Vitronectin (rhVTN-N, Life Technologies, no. A14700) and HUES1 on Matrigel (BD Biosciences, no. 734-1440) substrates, in mTeSR1 or TeSR2 medium (STEMCELL Technologies, nos. 8850 and 5860). Cell differentiation to kidney in 2D cultures was performed as described in [Takasato et al. \(2014\)](#), with a starting cell density of $18,000 \text{ cm}^{-2}$, while differentiation in 3D cultures was modified from [Takasato et al. \(2015\)](#). For a detailed description of stem cell culture and differentiation protocols, see [Supplemental Information](#).

Lentiviral Vector Production and Transduction of hESCs

Construction of the lentiviral shuttle plasmid pRRL.sin.cppt.EF1 α -iRFP-E2A-Luc, expressing iRFP and luciferase under the control of the EF1 α promoter is described in [Supplemental Information](#). Third-generation lentiviral vectors were constructed as described previously ([Dajas-Bailador et al. \(2014\)](#) and [Supplemental Information](#)). HESCs were transduced at an MOI of 5 IU/cell.



RNA Extraction and Real-Time PCR

RNA samples from cultures were collected at 0, 1, 3, 5, 7, 10, 13, 16, 19, 24, and 30 days after initiation of differentiation. RNA was extracted using the miRvana miRNA isolation kit (Thermo Fisher, AM1560) according to the manufacturer's instructions. Real-time qPCR was performed using the TaqMan RNA-to-Ct 1-Step Kit (Thermo Fisher, 4392653) according to the manufacturer's instructions, on a Bio-Rad C1000 Thermal Cycler fit with a CFX384 Real Time System, using 15 ng of RNA per reaction. The primers used are shown in [Table S2](#).

Immunostaining of Cultures and Viability/Toxicity Assays

See [Supplemental Information](#) and [Table S3](#).

Implantation of hPSCs and Kidney Progenitor Cells into Immunocompromised Mice

All surgery was carried out under UK Home Office Licence (70/7838) obtained after local ethics committee approval. SCID/beige mice were injected subcutaneously at four sites each, with MAN13 hESCs (1.0×10^6 cells/site) or MAN13-derived kidney progenitors (day 12 or 19 of the differentiation protocol; 3.0×10^6 cells/site). The cells had been previously resuspended in a 2:1 mix of DMEM-F12:Matrigel (see [Supplemental Information](#)).

In Vivo Bioluminescence Imaging of Mice, Histology, and Electron Microscopy

See [Supplemental Information](#).

SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, six figures, three tables, and one movie and can be found with this article online at <https://doi.org/10.1016/j.stemcr.2018.01.008>.

AUTHOR CONTRIBUTIONS

I.B., A.S.W., and S.J.K. designed the study. I.B., P.R., F.T., E.S., D.F., P.L., A.P., and Q.W. conducted the research. I.B., P.R., D.F., M.-C.A., R.L., A.S.W., and S.J.K. analyzed the data. I.B., P.R., A.S.W., and S.J.K. wrote the paper. All authors approved the final paper.

ACKNOWLEDGMENTS

We thank Aleksandr Mironov and Bernard Davenport for carrying out the TEM. We acknowledge grant support as follows: Research Councils UK/Medical Research Council (MRC) MR/K026739/1 UK Regenerative Medicine Platform Hub, Safety and Efficacy of Stem Cells; MRC MICA grant MR/M017344; Kidneys for Life pump priming grant KfL/1/15; Manchester Regenerative Medicine Network strategic funding initiative grant MARMN/1/17; and Kidney Research UK project grant JFS/RP/008/20160916.

Received: August 24, 2017
Revised: January 11, 2018
Accepted: January 12, 2018
Published: February 8, 2018

REFERENCES

Barboux, S., Niaudet, P., Gubler, M.C., Grünfeld, J.P., Jaubert, F., Kuttann, F., Fékété, C.N., Souleyreau-Therville, N., Thibaud, E., Fellous, M., and McElreavey, K. (1995). Donor splice-site mutations in WT1 are responsible for Frasier syndrome. *Nat. Genet.* *17*, 467–470.

Baxter, M.A., Camarasa, M.V., Bates, N., Small, F., Murray, P., Edgar, D., and Kimber, S.J. (2009). Analysis of the distinct functions of growth factors and tissue culture substrates necessary for the long-term self-renewal of human embryonic stem cell lines. *Stem Cell Res.* *3*, 28–38.

Canham, M.A., Van Deusen, A., Brison, D.R., De Sousa, P.A., Downie, J., Devito, L., Hewitt, Z.A., Ilic, D., Kimber, S.J., Moore, H.D., et al. (2015). The molecular karyotype of 25 clinical-grade human embryonic stem cell lines. *Sci. Rep.* *5*, 17258.

Carpenter, M.K., Frey-Vasconcells, J., and Rao, M.S. (2009). Developing safe therapies from human pluripotent stem cells. *Nat. Biotechnol.* *27*, 606–613.

Cheng, A., Hardingham, T.E., and Kimber, S.J. (2014). Generating cartilage repair from pluripotent stem cells. *Tissue Eng. Part B Rev.* *20*, 257–266.

Ciampi, O., Iacone, R., Longaretti, L., Benedetti, V., Graf, M., Magnone, M.C., Patsch, C., Xinaris, C., Remuzzi, G., Benigni, A., and Tomasoni, S. (2016). Generation of functional podocytes from human induced pluripotent stem cells. *Stem Cell Res.* *17*, 130–139.

Cowan, C.A., Klimanskaya, I., McMahon, J., Atenza, J., Witmyer, J., Zucker, J.P., Wang, S., Morton, C.C., McMahon, A.P., Powers, D., and Melton, D.A. (2004). Derivation of embryonic stem cell lines from human blastocysts. *N. Engl. J. Med.* *350*, 1353–1356.

Dajas-Bailador, F., Bantounas, I., Jones, E.V., and Whitmarsh, A.J. (2014). Regulation of axon growth by the JIP1-Akt axis. *J. Cell Sci.* *127*, 230–239.

Dekel, B., Amariglio, N., Kaminski, N., Schwartz, A., Goshen, E., Arditti, F.D., Tsarfaty, I., Passwell, J.H., Reisner, Y., and Rechavi, G. (2002). Engraftment and differentiation of human metanephroi into functional mature nephrons after transplantation into mice is accompanied by a profile of gene expression similar to normal human kidney development. *J. Am. Soc. Nephrol.* *13*, 977–990.

Dekel, B., Burakova, T., Arditti, F.D., Reich-Zeliger, S., Milstein, O., Aviel-Ronen, S., Rechavi, G., Friedman, N., Kaminski, N., Passwell, J.H., and Reisner, Y. (2003). Human and porcine early kidney precursors as a new source for transplantation. *Nat. Med.* *9*, 53–60.

Ebert, A.D., Yu, J., Rose, F.F., Jr., Mattis, V.B., Lorson, C.L., and Thomson, J.A. (2009). Induced pluripotent stem cells from a spinal muscular atrophy patient. *Nature* *457*, 277–280.

Eremina, V., Sood, M., Haigh, J., Nagy, A., Lajoie, G., Ferrara, N., Gerber, H.P., Kikkawa, Y., Miner, J.H., and Quaggin, S.E. (2003). Glomerular-specific alterations of VEGF-A expression lead to distinct congenital and acquired renal diseases. *J. Clin. Invest.* *111*, 707–716.

Faguer, S., Pillet, A., Chassaing, N., Merhenberger, M., Bernadet-Monrozies, P., Guitard, J., and Chauveau, D. (2009). Nephropathy in Townes-Brocks syndrome (SALL1 mutation): imaging and pathological findings in adulthood. *Nephrol. Dial. Transplant.* *24*, 1341–1345.



- Fiegel, H.C., Prymachuk, G., Rath, S., Bleiziffer, O., Beier, J.P., Bruns, H., Kluth, D., Metzger, R., Horch, R.E., Till, H., and Kneser, U. (2010). Foetal hepatocyte transplantation in a vascularized AV-Loop transplantation model in the rat. *J. Cell Mol. Med.* 14, 267–274.
- Freedman, B.S., Brooks, C.R., Lam, A.Q., Fu, H., Morizane, R., Agrawal, V., Saad, A.F., Li, M.K., Hughes, M.R., Werff, R.V., et al. (2015). Modelling kidney disease with CRISPR-mutant kidney organoids derived from human pluripotent epiblast spheroids. *Nat. Commun.* 6, 8715.
- Harvey, S.J., Zheng, K., Sado, Y., Naito, I., Ninomiya, Y., Jacobs, R.M., Hudson, B., and Thorner, P.S. (1998). Role of distinct type IV collagen networks in glomerular development and function. *Kidney Int.* 54, 1857–1866.
- Hildebrandt, F. (2010). Genetic kidney diseases. *Lancet* 375, 1287–1295.
- Ichimura, H., and Shiba, Y. (2017). Recent progress using pluripotent stem cells for cardiac regenerative therapy. *Circ. J.* 81, 929–935.
- Kang, M., and Han, Y.M. (2014). Differentiation of human pluripotent stem cells into nephron progenitor cells in a serum and feeder free system. *PLoS One* 9, e94888.
- Kerecuk, L., Schreuder, M.F., and Woolf, A.S. (2008). Renal tract malformations: perspectives for nephrologists. *Nat. Clin. Pract. Nephrol.* 4, 312–325.
- Kobayashi, A., Valerius, M.T., Mugford, J.W., Carroll, T.J., Self, M., Oliver, G., and McMahon, A.P. (2008). Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. *Cell Stem Cell* 3, 169–181.
- Lam, A.Q., Freedman, B.S., Morizane, R., Lerou, P.H., Valerius, M.T., and Bonventre, J.V. (2014). Rapid and efficient differentiation of human pluripotent stem cells into intermediate mesoderm that forms tubules expressing kidney proximal tubular markers. *J. Am. Soc. Nephrol.* 25, 1211–1225.
- Lemmink, H.H., Mochizuk, I.T., van den Heuvel, L.P., Schröder, C.H., Barrientos, A., Monnens, L.A., van Oost, B.A., Brunner, H.G., Reeders, S.T., and Smeets, H.J. (1994). Mutations in the type IV collagen $\alpha 3$ (COL4A3) gene in autosomal recessive Alport syndrome. *Hum. Mol. Genet.* 3, 1269–1273.
- Liyanage, T., Ninomiya, T., Jha, V., Neal, B., Patrice, H.M., Okpechi, I., Zhao, M.H., Lv, J., Garg, A.X., Knight, J., et al. (2015). Worldwide access to treatment for end-stage kidney disease: a systematic review. *Lancet* 385, 1975–1982.
- McMahon, A.P. (2016). Development of the mammalian kidney. *Curr. Top. Dev. Biol.* 117, 31–64.
- Morizane, R., Lam, A.Q., Freedman, B.S., Kishi, S., Valerius, M.T., and Bonventre, J.V. (2015). Nephron organoids derived from human pluripotent stem cells model kidney development and injury. *Nat. Biotechnol.* 33, 1193–1200.
- Narayanan, K., Schumacher, K.M., Tasnim, F., Kandasamy, K., Schumacher, A., Ni, M., Gao, S., Gopalan, B., Zink, D., and Ying, J.Y. (2013). Human embryonic stem cells differentiate into functional renal proximal tubular-like cells. *Kidney Int.* 83, 593–603.
- Neild, G.H. (2017). Life expectancy with chronic kidney disease: an educational review. *Pediatr. Nephrol.* 32, 243–248.
- Oldershaw, R.A., Baxter, M.A., Lowe, E.T., Bates, N., Grady, L.M., Soncin, F., Brison, D.R., Hardingham, T.E., and Kimber, S.J. (2010). Directed differentiation of human embryonic stem cells toward chondrocytes. *Nat. Biotechnol.* 28, 1187–1194.
- Ovunc, B., Otto, E.A., Vega-Warner, V., Saisawat, P., Ashraf, S., Ramaswami, G., Fathy, H.M., Schoeb, D., Chernin, G., Lyons, R.H., et al. (2011). Exome sequencing reveals cubilin mutation as a single-gene cause of proteinuria. *J. Am. Soc. Nephrol.* 22, 1815–1820.
- Sanyanusin, P., Schimmenti, L.A., McNoe, L.A., Ward, T.A., Pierpont, M.E., Sullivan, M.J., Dobyns, W.B., and Eccles, M.R. (1995). Mutation of the PAX2 gene in a family with optic nerve colobomas, renal anomalies and vesicoureteral reflux. *Nat. Genet.* 9, 358–364.
- Sariola, H. (1984). Incomplete fusion of the epithelial and endothelial basement membranes in interspecies hybrid glomeruli. *Cell Differ.* 14, 189–195.
- Sharmin, S., Taguchi, A., Kaku, Y., Yoshimura, Y., Ohmori, T., Sakuma, T., Mukoyama, M., Yamamoto, T., Kurihara, H., and Nishinakamura, R. (2016). Human induced pluripotent stem cell-derived podocytes mature into vascularized glomeruli upon experimental transplantation. *J. Am. Soc. Nephrol.* 27, 1778–1791.
- Shi, Y., Inoue, H., Wu, J.C., and Yamanaka, S. (2017). Induced pluripotent stem cell technology: a decade of progress. *Nat. Rev. Drug Discov.* 16, 115–130.
- St John, P.L., Wang, R., Yin, Y., Miner, J.H., Robert, B., and Abrahamson, D.R. (2001). Glomerular laminin isoform transitions: errors in metanephric culture are corrected by grafting. *Am. J. Physiol. Ren. Physiol.* 280, F695–F705.
- Taguchi, A., Kaku, Y., Ohmori, T., Sharmin, S., Ogawa, M., Sasaki, H., and Nishinakamura, R. (2014). Redefining the *in vivo* origin of metanephric nephron progenitors enables generation of complex kidney structures from pluripotent stem cells. *Cell Stem Cell* 14, 53–67.
- Takasato, M., Er, P.X., Becroft, M., Vanslambrouck, J.M., Stanley, E.G., Elefanty, A.G., and Little, M.H. (2014). Directing human embryonic stem cell differentiation towards a renal lineage generates a self-organizing kidney. *Nat. Cell Biol.* 16, 118–126.
- Takasato, M., Er, P.X., Chiu, H.S., Maier, B., Baillie, G.J., Ferguson, C., Parton, R.G., Wolvetang, E.J., Roost, M.S., Chua de Sousa Lopes, S.M., and Little, M.H. (2015). Kidney organoids from human iPSCs contain multiple lineages and model human nephrogenesis. *Nature* 526, 564–568.
- Tufró, A. (2000). VEGF spatially directs angiogenesis during metanephric development *in vitro*. *Dev. Biol.* 227, 558–566.
- Turner, J.J., Stacey, J.M., Harding, B., Kotanko, P., Lhotta, K., Puig, J.G., Roberts, I., Torres, R.J., and Thakker, R.V. (2003). Uromodulin mutations cause familial juvenile hyperuricemic nephropathy. *J. Clin. Endocrinol. Metab.* 88, 1398–1401.
- Woolf, A.S., and Davies, J.A. (2013). Cell biology of ureter development. *J. Am. Soc. Nephrol.* 24, 19–25.
- Woolf, A.S., and Jenkins, D. (2015). Development of the kidney. In *Heptinstall's Pathology of the Kidney*, 7th Edition, J.C. Jennette,



- J.L. Olson, F.G. Silva, and V.D. D'Agati, eds. (Wolters Kluwer), pp. 67–89.
- Woolf, A.S., Palmer, S.J., Snow, M.L., and Fine, L.G. (1990). Creation of a functioning chimeric mammalian kidney. *Kidney Int.* **38**, 991–997.
- Xia, Y., Sancho-Martinez, I., Nivet, E., Rodriguez Esteban, C., Campistol, J.M., and Izpisua Belmonte, J.C. (2014). The generation of kidney organoids by differentiation of human pluripotent cells to ureteric bud progenitor-like cells. *Nat. Protoc.* **9**, 2693–2704.
- Xinaris, C., Benedetti, V., Novelli, R., Abbate, M., Rizzo, P., Conti, S., Tomasoni, S., Corna, D., Pozzobon, M., Cavallotti, D., et al. (2016). Functional human podocytes generated in organoids from amniotic fluid stem cells. *J. Am. Soc. Nephrol.* **27**, 1400–1411.
- Ye, J., Bates, N., Soteriou, D., Grady, L., Edmond, C., Ross, A., Kerby, A., Lewis, P.A., Adeniyi, T., Wright, R., et al. (2017). High quality clinical grade human embryonic stem cell lines derived from fresh discarded embryos. *Stem Cell Res. Ther.* **8**, 128.
- Zenker, M., Aigner, T., Wendler, O., Tralau, T., Müntefering, H., Fenski, R., Pitz, S., Schumacher, V., Royer-Pokora, B., Wühl, E., et al. (2004). Human laminin $\beta 2$ deficiency causes congenital nephrosis with mesangial sclerosis and distinct eye abnormalities. *Hum. Mol. Genet.* **13**, 2625–2632.

Stem Cell Reports, Volume 10


Supplemental Information

**Generation of Functioning Nephrons by Implanting Human Pluripotent
Stem Cell-Derived Kidney Progenitors**

Ioannis Bantounas, Parisa Ranjzad, Faris Tengku, Edina Silajdžić, Duncan Forster, Marie-Claude Asselin, Philip Lewis, Rachel Lennon, Antonius Plagge, Qi Wang, Adrian S. Woolf, and Susan J. Kimber

Figure S1

HUES1



Relative Expression
(Log₂(-Δct))

Time (days)

Figure S2




Figure S3




Figure S4




Figure S5








Figure S6

A



SUPPLEMENTAL FIGURE LEGENDS

Figure S1. (Related to Figure 1). QPCR profiling of HUES1 and MAN11 hPSCs differentiating in the 2D kidney protocol. Cells were differentiated for 19 days and expression of 17 species of transcripts, normalised against GAPDH, was assessed. Biological repeats for HUES1 cells are shown in blue and red.

Figure S2. (Related to Figure 2). Immunocytochemistry of hPSC derivatives after 30 days of 2D culture. Note clusters of nephron progenitors ($WT1^+$) and UB epithelium ($CDH1^+/GATA3^+$ and $CDH1^+/PAX2^+$), with scattered $SIX2^+$ cells between these clusters. Bar is 40 μm .

Figure S3. (Related to Figure 2). Analyses of hPSC-derived kidney cells in 3D cultures. **A.** Phase contrast image of the edge of an organoid at the end of the culture period (d25). Note the complex internal structure. **B-K.** Histology sections of organoids, with blue haematoxylin nuclei counterstain in B and J. **B.** IHC for collagen alpha-3 (IV) shows only background (unspecific signal). **C.** IHC for pan-collagen IV shows positive signals (brown) in glomeruli and tubules. **D.** IHC for laminin B2 shows positive signals (brown) in glomerulus but not in an adjacent tubule. **E.** IHC for synaptopodin shows positive cells in glomerular tufts. **F.** Cells in glomerular tufts immunostain for $WT1$. **G.** Glomerular cells positive for podocalyxin IHC. **H.** IHC for $Ki67$ detects proliferating cells in the interstitium between a glomerulus and a tubule. **I.** Lack of background signal with anti-rabbit secondary antibody and omission of primary antibody. **J.** PECAM IHC detected capillary-like structures (red asterisk) in the interstitium near a glomerulus, and around the glomerular capsule, but the glomerular tuft itself is negative. **K.** No significant signal when immunostaining for VEGFA. *g*: glomerular-like structures and *t*: tubules. Bars are 20 μm in A and 50 μm in other frames.

Figure S4. (Related to Figures 3 and 4). Subcutaneous implantation into *beige/SCID* mice of luciferase labelled MAN13 hPSCs. **A.** Histological overview of teratoma four weeks after implantation stained with haematoxylin and eosin. The teratoma contains a variety of tissues from the three primary embryonic germ layers. The boxed areas indicate: **B.** gland-like endoderm; **C.** muscle mesoderm; and **D.** neuro-epithelial-like ectoderm. **E.** Luciferase-labelled implanted cells were detected in living animals four weeks after implantation after luciferin injection and non-invasive imaging by their bioluminescence; dorsal and side views are shown. **F.** Immunostaining of teratomas (brown) for luciferase. **G.** Immunostaining (brown) for human mitochondria. Note that sections in F. and G. are not counterstained. Scale bars: A, 500 μm ; B, C, D, F and G 50 μm .

Figure S5. (Related to Figure 4). A kidney-like structure grown from subcutaneously implanted MAN13-derived kidney precursor cells harvested at day 12 in 2D culture. A-D were counterstained with haematoxylin and eosin, while E-G were not counterstained. **A.** Compared with that depicted in Figure 6, this implant appeared less differentiated. **B-D.** Despite clusters of glomeruli and tubules (B), other areas contained cartilage (C) or zones of glomeruli surrounded by mesenchyme-like cells and primitive tubules (D). **E-G.** Within the latter zone, tubules expressed $CDH1$ (brown in E), both tubules (dotted outlines) and mesenchyme were rich in $Ki67$ expressing cells (brown in F), and tubules immunostained weakly for $PAX2$ (brown in G). Scale bars: A, 100 μm ; B-G, 50 μm .

Figure S6. (Related to Figure 4). Subcutaneous implantation into *beige/SCID* mice of luciferase-labelled MAN13-derived kidney precursor cells harvested at day 19 in 2D culture. **A.** Overview. **B and C.** Primitive nephrons. **D.** Undifferentiated mesenchyme-like cells. Compare this tissue mass that contains only very primitive nephrons and tubules with tissues resulting from day 12 implants (see Figure 6). Bars are 100 μm in A and 50 μm in B-D.

SUPPLEMENTAL VIDEO LEGEND

Supplemental Video. (Related to Figure 5). Three D reconstruction of a forming glomerulus in an implant from day 12 PSC-kidney progenitors. Note the capillary and mesangial-like cell in the core of the glomerulus.

Table S1. (Related to Figure 4). Summary of implant experiments.

Cell type injected	# of animals	Sites per animal	# of cells per site	# of sites with cell masses	Diameter of cell mass (cm ± S.E.)	Time of excision (days post-injection ± S.E.)
MAN13 (unlabelled) hESCs	6	4	1×10^6	20/24	1.13 ± 0.07	38.8 ± 1.2
MAN13 + LV-iRFP/Luc hESCs	9	4	1×10^6	29/36	0.98 ± 0.07	44.6 ± 1.2
MAN13+LV-iRFP/Luc-derived day-12 kidney progenitors (1 st run)	8	4	3×10^6	9/32	0.61 ± 0.11	84.3 ± 0.2
MAN13+LV-iRFP/Luc-derived day-12 kidney progenitors (2 nd run)	5	4	3×10^6	7/20	N/A	79 ± 0.0
MAN13+LV-iRFP/Luc-derived day-19 kidney progenitors	5	4	3×10^6	8/20	N/A	84 ± 0.0

Table S2. (Related to experimental Procedures). Sequences of primers used for QPCR experiments.

Primer	Sequence
OSR1 Fwd	CTCCTCGAGATCCGGATTGAG
Rev	GTTCACTGCCTGAAGGAAGG
T Fwd	AGGTACCCAACCCTGAGGA
Rev	GCAGGTGAGTTGTCAGAATAGGT
MIXL1 Fwd	GGTACCCCGACATCCACTT
Rev	GCCTGTTCTGGAACCATAACCT
PAX2 Fwd	GCAACCCCGCCTTACTAAT
Rev	AACTAGTGGCGGTCATAGGC
LHX1 Fwd	ATGCAACCTGACCGAGAAGT
Rev	CAGGTGCTAGGGGAGATG
SIX2 Fwd	CGCCCATGTGGGTCAGTGGG
Rev	AGCCGGGAGCGCTGTAGTCA
HOXD11 Fwd	GCCAGTGTGCTGTCGTTCCC
Rev	CTTCCTACAGACCCCGCCGT
HOXB7 Fwd	GCCTACAAATCATCCGGCCA
Rev	GGTTGGAAGCAAACGCACAA
FOXD1 Fwd	GACTCTGCACCAAGGGACTG
Rev	CCTCGAGCGCGCTAACATAG
GAPDH Fwd	AGCCACATCGCTCAGACAC
Rev	GCCCAATACGACCAAATCC
WT1 Fwd	GGCAGCACAGTGTGTGAACT
Rev	CCAGGCACACCTGGTAGTTT
SALL1 Fwd	AGCGAAGCCTCAACATTTCCAATCC
Rev	AATTCAAAGAACTCGGCACAGCACC
SALL4 Fwd	CAGATCCACGAGCGGACTCA
Rev	CCCCGTGTGTCATGTAGTGA
AQP1 Fwd	ATTAACCCTGCTCGGTCCTT
Rev	ACCCTGGAGTTGATGTCGTC
PODXL Fwd	TCATCATCACCATCGTCTGC
Rev	CCACCTTCTTCTCCTGCATC
AQP2 Fwd	GTGCGCCGAAAATTTCCA
Rev	CCTCGACTTCTCCTTGAAGCA
UMOD Fwd	AACATCACTGATATCTCCCTCCT
Rev	TTGTCTCTGTCATTGAAGCCC
PDGFRB Fwd	GCCGTCAAGATGCTTAAATCC
Rev	TATAGATGGGTCCTCCTTTGGT

Table S3. (Related to experimental Procedures). Antibodies used in immunocytochemical (ICC) and immunohistochemical (IHC) analyses

Antibody	Host	Source	Catalogue #	Application	Dilution
AQP1	Rabbit	Abcam	ab15080	IHC	1:500
CD31 (PECAM)	Mouse	Cell Signalling	3528	IHC	1:100
CDH1 (E-Cadherin)	Mouse	Abcam	76055	ICC	1:300
				IHC	1:1000
Collagen IV	Rabbit	Abcam	ab6586	IHC	1:400
Collagen IV α 3	Rat	Chondrex	7076	IHC	1:400
Cubulin	Goat	Santa Cruz	sc-20607	IHC	1:100
Firefly Luciferase	Rabbit	Abcam	21176	IHC	1:10000
GATA3	Goat	R&D Systems	AF2605	ICC	1:200
				IHC	1:200
Human Mitochondria	Mouse	Millipore	MAB1273	IHC	1:200
Ki-67	Rabbit	AbCam	16667	IHC	1:100
Laminin β 2	Mouse	Novus Biologicals	NBP2-42387	IHC	1:5000
Nephrin	Sheep	R&D Systems	AF4269	ICC	1:200
				IHC	1:500
PAX2	Rabbit	Thermo-Fisher	71-6000	ICC	1:200
				IHC	1:400
Podocalyxin	Mouse	R&D Systems	MAB1658	IHC	1:200
Podocin	Rabbit	Sigma	P0372	ICC	1:200
				IHC	1:500
PDGFRB	Goat	R&D Systems	AF385	IHC	1:100
SIX2	Rabbit	Proteintech	11561-1-AP	ICC	1:200
Synaptopodin (H-140)	Rabbit	Santa Cruz	sc-50459	IHC	1:200
TRPV5	Rabbit	Abcam	ab137028	ICC	1:200
				IHC	1:500
Uromodulin	Rabbit	Santa Cruz	sc-20631	IHC	1:100
VEGF-A	Mouse	R&D Systems	MAB293	IHC	1:100
WT1	Rabbit	Santa Cruz	sc-192	ICC	1:100
WT1	Rabbit	Calbiochem	CA1026	IHC	1:1000

SUPPLEMENTAL EXPERIMENTAL PROCEDURES

hPSC culture and differentiation

Stem cells were grown on 24-well or 6-well plates coated with 5 $\mu\text{g ml}^{-1}$ recombinant human Vitronectin (rhVTN-N, Life Technologies, #A14700) in the case of MAN11 and MAN13 or with Matrigel BD Biosciences, #734-1440) in the case of HUES1, in mTeSR1 (StemCell Technologies, #5850) or TeSR2 medium (StemCell Technologies, #5860), with the medium changed every two days. The cells were passaged by treatment of the cultures with 0.5mM EDTA solution, pH8 (Invitrogen, #15575-038; diluted in PBS) and replating the cells in mTeSR1 or TeSR2 medium, containing 5nM ROCK inhibitor, Y-27632 (Tocris, #1254) for 24h.

For 2D differentiation, stem cells were plated on vitronectin-coated plates, at a density of 18,000 cells cm^{-2} in mTeSR1 or TeSR2 medium containing 10 μM Y-27632. The following day the medium was replaced with STEMdiff™ APEL™ (StemCell Technologies, #05210), containing 8 μM CHIR-99021 (Tocris, #4423) for three days, followed by APEL™ supplemented with 200 ng ml^{-1} FGF9 (Peprotech, #100-23) and 1 $\mu\text{g ml}^{-1}$ heparin (Sigma, #3149) for a further 10 days. Subsequently, the cells were cultured in basal APEL™ medium which was changed daily. Differentiation in 3D cultures was performed according to Takasato et al (2015). Cells were differentiated for the first 7 days as in the 2D protocol above and then dissociated with TrypLE (Life Technologies, #12605-028). Aliquots of 2.5×10^5 cells were centrifuged at 400g for 2 min and the pellets were subsequently cultured on a medium-air interface by transfer onto a MilliCell cell culture insert (0.4 μm pore size; Millipore, #PICM03050) inserted into the wells of 6-well plates. Upon transfer, the cells were exposed to APEL™ medium containing 5 μM CHIR-99021 for 1h, before reverting back to APEL™ with FGF9/Heparin for a further 5 days. Finally, the 3D cultures were maintained in basal APEL™ medium for another 13 days.

Immunostaining of cultures

Cells were washed twice in PBS and then fixed in 4% paraformaldehyde (PFA) for 20 minutes, followed by another two PBS washes. The fixed cells were blocked and permeabilised for 30 min with 3% bovine serum albumin (BSA)/0.3% Triton-X in PBS before overnight incubation at 4°C with primary antibodies (Table S3) diluted in 3% BSA/PBS. They were then washed three times with PBS/0.1% Triton-X, followed by Alexa-Fluor™-488- or Alexa-Fluor™-594-labelled, species-specific secondary antibodies (Life Technologies; 1:300 dilution in 3% BSA/PBS). Images were collected on a Zeiss Axioimager.D2 upright microscope using a 63x/Plan-neofluar objective and captured using a Coolsnap HQ2 camera (Photometrics) through Micromanager software v1.4.23. Images were then processed and analysed using *ImageJ* (<http://imagej.net/Fiji/Downloads>).

Construction of the lentiviral shuttle plasmid

First, the iRFP720 coding sequence was excised from piRFP720-N1 (a gift from Vladislav Verkhusha, Addgene plasmid # 45461; Shcherbakova and Verkhusha, 2013) by EcoRI/XbaI digestion and was cloned into the pHIV-Luciferase vector (a gift from Bryan Welm, Addgene plasmid # 21375), upstream of its IRES element, to obtain the pHIV-iRFP720-IRES-Luc plasmid. To achieve a more efficient translation of the Luciferase coding sequence, the IRES was then replaced with an E2A peptide motif, using a two-step PCR protocol to create the pHIV-iRFP720-E2A-Luc plasmid.

To construct the 3rd generation lentiviral shuttle plasmid pRRL.sin.cppt.EF1 α -iRFP-E2A-Luc, the EF1 α promoter was first extracted from the pHIV-iRFP-IRES-Luc by PCR, using primers carrying ClaI/XbaI sites at their ends. The PCR product was digested with these enzymes and ligated into ClaI/XbaI-digested pRRL.sin.cppt.CMV-EGFP-WPRE (a gift from James Uney, University of Bristol) to yield pRRL.sin.cppt.EF1 α -EGFP-WPRE. Next, pHIV-EF1 α -iRFP-E2A-Luc was digested with EcoRI/ClaI, blunt-ended and the EF1 α -iRFP-E2A-Luc-containing fragment was ligated into the BamHI/SalI-digested and blunt-ended pRRL.sin.cppt.EF1 α -EGFP-WPRE vector.

Lentiviral vector production

Lentiviral vectors were produced by transfection of HEK-293T cells by calcium phosphate precipitation, in 15cm dishes, at 50% confluency, with 10 μg pRRL.sin.cppt.EF1 α -iRFP-E2A-Luc, 10 μg pMDLg-pRRE, 3.4 μg pMD2.G and 2 μg pRSV-Rev per dish. Cell medium was collected over two days and centrifuged at 6,000g overnight, the pellet resuspended in PBS and the new suspension centrifuged in a SW40-Ti rotor (Beckman Coulter Ltd, High Wycombe, UK) at 50,000g for 90min. Finally, the resulting pellet was resuspended in PBS, at 1:2,000 of the original medium volume. The viral titre was calculated by FACS (detecting iRFP fluorescence) on HEK-293T cells transduced with serial dilutions of the viral preparation. HESCs were transduced with lentivirus at a multiplicity of infection (MOI) of 5 IU/cell.

Viability/Toxicity assays

Cells were plated on vitronectin-coated 24-well plates at 3.5×10^4 cells per well and grown for six days in mTeSR1 medium, replacing the medium daily. Viability/toxicity assays were then carried out using the ApoTox-Glo™ kit (Promega) according to the manufacturer's instructions. Prior to the start of the assay, the volume of medium in the well was reduced to 200 μ l and 40 μ l of the viability/toxicity reagent were added. The cells were replaced in the incubator for 1h, before absorbance was measured directly from the culture plate wells in a GLOMAX Multi+ reader using the 400_{Ex}/505_{Em} (viability) and 485_{Em}/520_{Ex} (toxicity) filters.

Implantation of hPSCs and kidney progenitor cells into immunocompromised mice

All surgery was carried out under UK Home Office Licence (70/7838) obtained after local ethics committee approval. MAN13 hESCs or MAN13-derived kidney progenitors (day-12 or day-19 of the differentiation protocol) were collected using TrypLE (Life Technologies, #12605-028) for one or five minutes, respectively, centrifuged at 200 g and resuspended in warm DMEM-F12 culture medium. Cells were then counted and separated into 400 μ l aliquots of cold DMEM-F12 containing 6.0×10^6 or 1.8×10^7 cells, respectively. Two hundred μ l of Matrigel (Becton Dickinson, 356231) was added to the cell suspension prior to injection into 6-week old, female, immunocompromised SCID-Beige mice. Next, 100 μ l of the final cell suspension (equivalent to 1.0×10^6 or 3.0×10^6 cells, respectively) was injected subcutaneously into each of four dorsal sites per mouse, using a syringe fitted with a 23G needle. The first two injection sites were on the left and right shoulder blades and the second two injection sites, approximately 1.5 cm below each of the first two. Prior to injection, the animals were anaesthetised with isoflurane gas.

In vivo bioluminescence imaging of mice

All mice were administered with 100 μ L of 10 mg/kg luciferin in PBS intraperitoneally, and some mice were also injected with 100 μ L FITC dextran intravenously. The mice were then anaesthetized using 2% isoflurane in O₂ at 2 L/min, before being transferred to the heated imaging bed in order to maintain core temperature. From 5-15 minutes after injection, the mice were scanned in a Biospace Lab PhotonImager Optima (Biospace Lab, Nesles-la-Vallée, France) with the 4D attachment to allow imaging on four sides of the mouse. Mice were culled approximately 1 hour after injection.

Histology and immunohistochemistry

Tissue was fixed in 4% paraformaldehyde, embedded in paraffin and sectioned at 5 μ m. Sections were dewaxed and rehydrated, and alternate slides were stained with haematoxylin and eosin (H&E) to assess overall tissue architecture. Images were acquired on a 3D-Histech Panoramic-250 microscope slide-scanner using a x20 objective (Zeiss) and selected images were captured using the Case Viewer software (3D-Histech). After rehydration, other slides were boiled in an 800W microwave in 10 mM sodium citrate buffer (pH 6.0). After cooling to room temperature, endogenous peroxidase activity was blocked using 0.3% H₂O₂ in PBS for 10 minutes. Sections were permeabilized using 0.2% Triton X-100 (Sigma-Aldrich) for 10 minutes and blocked using 1% bovine serum albumin (BSA) with 10% serum from the species in which the secondary antibody was raised. Sections were incubated overnight at 4°C with the primary antibody + 1% BSA. Primary antibodies used are listed in Table S3. Biotin-conjugated species specific secondary antibodies with 1% BSA were incubated at room temperature for 2 hours. Following PBS washes, slides were incubated in avidin-biotin enzyme complex (Vector Laboratories VECTASTAIN Elite ABC Reagent, PK-6100) for 1 hour at room temperature. Peroxidase activity was detected with the 3, 3'-diaminobenzidine (DAB) peroxidase substrate solution (Vector Laboratories, SK4100) in some cases with haematoxylin counterstain. Sections were dehydrated and mounted with DPX mounting medium and examined under a Leica DMLB 2 microscope. Negative controls omitted primary antibodies. For immunofluorescent imaging, anti-rabbit Alexa 488 (A11034, Thermo Fisher Scientific) and anti-mouse Alexa 594 (A11032, Thermo Fisher Scientific) secondary antibodies and DAPI nuclear stain were used. Sections were mounted with Vectashield antifade mounting medium (H-1000, Vector Laboratories).

Images were collected on a Zeiss Axioimager.D2 upright microscope and captured using a Coolsnap HQ2 camera (Photometrics) through Micromanager software v1.4.23. Specific band pass filter sets for *DAPI*, *FITC* and *Texas red* were used to prevent bleed through from one channel to the next. Images were then processed and analysed using *Fiji ImageJ* (<http://imagej.net/Fiji/Downloads>). For visualisation of the FITC dextran by fluorescent microscopy, dewaxed and rehydrated paraffin embedded sections were mounted with Vectashield antifade mounting medium. Images were acquired on an Olympus IX83 inverted microscope. The images were collected using a R6 CCD camera with a Z optical spacing of 0.2 μ m. Raw images were then deconvolved using the Huygens Pro software (SVI).

Transmission electron microscopy and serial block face-scanning *electron microscopy*

Organoid implants were cut into 1 mm cubes and fixed in situ by using 2% (wt/vol) glutaraldehyde (Agar Scientific, UK) in 0.1 M cacodylate buffer (pH 7.2); stained in 1% (wt/vol) osmium tetroxide, 1.5% (wt/vol) potassium ferrocyanide in 0.1 M cacodylate buffer, followed by 1 % (wt/vol) thiocarbohydrazide. After they were stained further in 1% (wt/vol) osmium tetroxide, and soaked in 1% (wt/vol) uranyl acetate overnight. In the final staining step incubation was performed at 60°C with lead aspartate pH 5.5 for one hour (Starborg et al., 2013). Samples were dehydrated in ethanol, infiltrated in TAAB 812 hard resin and sectioned at 70-80nm thickness. Sections were examined using a FEI Tecnai 12G2 Biotwin transmission electron microscope at magnification from 145X to 6800X. For Serial Block face scanning electron microscopy following preparation as above the block was placed in the Quanta 250 FEG (FEI Company) + Gatan 3view system and a 41 $\mu\text{m} \times 41 \mu\text{m}$ field of view was chosen and imaged by using a 4096 \times 4096 scan, which gave an approximate pixel size of 10 nm. The section thickness was set to 50 nm in the Z (cutting) direction.

SUPPLEMENTAL REFERENCES

Shcherbakova, D.M., and Verkhusha, V.V. (2013). Near-infrared fluorescent proteins for multicolor *in vivo* imaging *Nat Methods* 10, 751-4.

Starborg, T., Kalson, N.S., Lu, Y., Mironov, A., Cootes, T.F., Holmes, D.F., and Kadler, KE. (2013). Using transmission electron microscopy and 3View to determine collagen fibril size and three-dimensional organization. *Nat Protoc* 8, 1433-1448.